Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

1-41-66 (USA)

The conference call (Call ID 204, followed by the #) will be available for play-back for 48 hours after the call by dialling:
+41-(0)91-612-43-30 (Europe)

+44-(0)207-108-62-33 (UK)

+1-(1)866-416-25-58 (USA)

About Arpida Ltd. Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007.

In June 2007, Arpida announced that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed four Phase I trials. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community
'/>"/>

SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014 Nerium International, the ... in the spotlight again. Nerium will showcase its ... NeriumFirmTM Body Contouring Cream to Hollywood’s elite at ... during the 66th Primetime Emmy® Awards. , Developed ... third-party clinical trials show that NeriumAD night cream ...
(Date:8/21/2014)... Institute for Molecular Medicine Finland (FIMM), University of ... novel "man and machine" decision support system for ... described in PLOS One scientific journal ... computer vision algorithms similar to those used in ... the diagnostically most relevant areas. Tablet computers can ...
(Date:8/21/2014)... , Aug. 21, 2014 Telomere ... of their Nutraceutical "TELO-20 for Dogs" with ... Telomere-lengthening supplement in the world for dogs. Telomeres ... every chromosome in the body. A wealth of ... experts in Telomere Science and Aging, including Nobel ...
(Date:8/21/2014)... HONG KONG , Aug. 21, 2014  China Cord ... today announced its plan to release financial results for ... August 28, 2014, after market close in the US.  ... call at 8:00 a.m. ET on Friday, August 29, ... brief overview of the Company,s recent developments, followed by ...
Breaking Biology Technology:Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2
... MILWAUKEE--- GE Healthcare , a $10 billion provider ... information technology, announced today that it has received ... healthcare industry authority, KLAS Enterprises for the second ... called Centricity(R) Pharmacy Information System, was recognized in ...
... OASYS , a leading developer of K-12 software ... Behind management, recently announced their online, ASP software ... (IEPs) and monitors the progress of children with ... in 16 Wisconsin school districts during 2003, provides ...
... Third Wave Technologies Inc , a maker of molecular ... 2D6 analysis panel, which provides clinical trial laboratories with ... for the important 2D6 gene. , ,The panel is ... the ability to configure custom assay panels. The panel ...
Cached Biology Technology:Third Wave Releases Gene Test 2
(Date:8/22/2014)... be able to purchase fuel cell cars from Toyota ... of the cars will run on hydrogen made from ... warming. , Now scientists at Stanford University have developed ... battery to produce hydrogen by water electrolysis. The ... split liquid water into hydrogen and oxygen gas. Unlike ...
(Date:8/21/2014)... of American singles found that during sex with ... rates. On average, men experience orgasm 85.1 percent ... little difference. For women, however, orgasm occurrence is ... percent of the time during sex with a ... women,s sexual orientation, with lesbian women experiencing orgasm ...
(Date:8/21/2014)... dandruff, eczema and other itchy, flaky maladies in humans ... Hawaiian coral reefs and the extreme environments of arctic ... the scientific journal PLOS Pathogens considers the ... genus Malassezia in light of new insights ... world. , University of Hawai,i at Mānoa scientist Anthony ...
Breaking Biology News(10 mins):Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4From dandruff to deep sea vents, an ecologically hyper-diverse fungus 2
... common contact allergy in adults. Research at the University ... which many deem harmless compared to synthetic perfumes, may ... adults in northern Europe is believed to suffer from ... common is nickel allergy, but many people also suffer ...
... Your mother always told you not to use your teeth ... Human skulls have small faces and teeth and are not ... of our earliest ancestors, say scientists. New research published in ... Academy of Sciences reveals nut-cracking abilities in our 250-million-year-old ...
... discovered a chemical that stops stem cells from turning into ... develop new medical treatments more easily. Stem cells have ... the body, and scientists believe they have huge potential to ... Professor Melanie Welham,s team at the University of ...
Cached Biology News:Even natural perfumes may cause allergies 2Early humans had 'jaws of steel' 2Don't go changing: New chemical keeps stem cells young 2
G-protein coupled purinergic receptor P2Y8...
Phospho-FAK (Tyr576/577) Antibody...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Biology Products: